(Q52893153)

9 May 2018

title

Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. (English)

1 reference

9 May 2018

6

Ignacio I Wistuba

1 reference

9 May 2018

Annikka Weissferdt

1

1 reference

9 May 2018

Junya Fujimoto

2

1 reference

9 May 2018

Neda Kalhor

3

1 reference

9 May 2018

Jaime Rodriguez

4

1 reference

9 May 2018

Roland Bassett

5

1 reference

9 May 2018

Cesar A Moran

7

1 reference

9 May 2018

publication date

10 March 2017

1 reference

9 May 2018

published in

Modern Pathology

1 reference

9 May 2018

volume

30

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

826-833

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2017.6

exact match

0 references

cites work

Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Epidemiology of thymoma and associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Molecular aspects of thymic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Diffuse high intensity PD-L1 staining in thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

Cancer: PD1 makes waves in anticancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Thymic carcinoma, part 2: a clinicopathologic correlation of 33 cases with a proposed staging system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.6

7 January 2021

Identifiers

DOI

10.1038/MODPATHOL.2017.6

1 reference

9 May 2018

1 reference

9 May 2018